Biotechnology, Cancer-Focused AI & Clinical Research

The Survé family’s biotechnology involvement brings together Genius Biotherapeutics, Bioclones, Ribotech and ACRO, forming an ecosystem focused on discovery, testing and delivery. Genius Biotherapeutics leads with AI-driven cancer research and therapies such as the dendritic cell vaccine Dendrovac, while Bioclones, founded in 1982 as South Africa’s oldest biotech, has pioneered biosimilars like Repotin® and is expanding into next-generation immunotherapies and oral vaccines. Ribotech produces biosimilars vital to cancer care, including G-CSF for chemotherapy patients.